Viemed Healthcare Inc Stock Price, News & Analysis

Viemed Healthcare (NASDAQ:VMD), a leader in home-based post-acute respiratory care, has completed its share repurchase program announced on June 9, 2025. The company successfully repurchased and cancelled all 1,976,441 authorized common shares, representing approximately 5% of total outstanding shares.

The repurchase was executed at a weighted average price of $6.69 per share, totaling approximately $13.2 million. CEO Casey Hoyt emphasized that this program completion reflects the company's confidence in its long-term outlook and commitment to shareholder value, supported by strong balance sheet and increasing free cash flow.

Viemed Healthcare (NASDAQ:VMD) reported strong Q2 2025 financial results, with record net revenues of $63.1 million, up 14.7% year-over-year. Net income reached $3.2 million ($0.08 per diluted share), a 115.1% increase from Q2 2024. The company's Adjusted EBITDA grew 11.5% to $14.3 million.

Operational highlights include significant patient growth, with ventilator patients up 11.4% to 12,152 and PAP therapy patients increasing 51.4% to 26,260. The company completed a $26 million acquisition of Lehan's Medical Equipment on July 1, 2025. Viemed raised its 2025 guidance, now expecting revenue between $271-277 million and Adjusted EBITDA of $59-62 million.

The company maintains a strong financial position with $20 million in cash and $55 million available in credit facilities.

Viemed Healthcare (NASDAQ:VMD), a provider of post-acute respiratory healthcare equipment and services in the United States, has scheduled its Second Quarter 2025 Earnings Conference Call for Thursday, August 7, 2025, at 11:00 a.m. EDT.

Participants can join via phone using US Toll-Free (877) 407-6176 or International +1 (201) 689-8451. A live audio webcast will be available, and a replay will be accessible through the company's investor relations website after the call.

Viemed Healthcare (NASDAQ:VMD) has completed the acquisition of Illinois-based Lehan's Medical Equipment for a base purchase price of $26 million, plus estimated contingent payments of $2.2 million. Lehan, with an 80-year history, generated $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024.

The acquisition strengthens Viemed's presence in post-acute respiratory healthcare, adding Lehan's three full-service locations in Northern Illinois and three sleep/CPAP setup locations in West Chicagoland and Wisconsin. Viemed plans to update its full-year 2025 guidance to reflect the acquisition's contribution when reporting Q2 2025 results.

[ "Acquisition adds $25.7M in revenue and $7.4M in Adjusted EBITDA from Lehan's 2024 performance", "Expands geographical footprint with 6 new locations in Illinois and Wisconsin", "Gains access to Lehan's preferred contracts and 80-year brand recognition", "Enhances service offerings with addition of women's health products and CPAP services" ]

Viemed Healthcare announced a share repurchase program authorizing the buyback of up to 1,976,441 common shares (5% of outstanding shares) through June 2026. The company plans to make purchases through open market and block trades, with daily purchases limited to 25% of the previous 4-week average daily volume. CEO Casey Hoyt highlighted strong Q1 2025 results and increased 2025 guidance, noting the company's disciplined capital allocation strategy. Viemed has previously repurchased 2.6 million shares since going public. With no net debt and full access to a $55 million credit facility, the company maintains sufficient liquidity for both the buyback program and growth initiatives, including the pending Lehan's Medical acquisition expected to close in Q3 2025.

Viemed Healthcare (NASDAQ:VMD), a leading provider of respiratory care and technology-enabled home medical equipment services, has announced its participation in the 15th Annual East Coast IDEAS Investor Conference. The company's presentation is scheduled for June 11, 2025, at 11:30am ET at The Westin Times Square in New York, NY. Investors and interested parties can access the presentation through the conference website at www.threepartadvisors.com/east-coast or via Viemed's investor relations section at viemed.com/investors.

Viemed Healthcare (NASDAQ:VMD) reported strong Q1 2025 financial results with net revenues of $59.1M, up 17% year-over-year. Net income reached $2.6M ($0.06 per diluted share), a 64% increase from Q1 2024. The company's Adjusted EBITDA grew 26% to $12.8M. Patient metrics showed solid growth with ventilator patients up 13% YoY to 11,809, and PAP therapy patients increasing 46% YoY to 22,899. Viemed maintains a strong financial position with $10.2M in cash and $55M available in credit facilities. The company raised its 2025 guidance, now expecting revenues of $256-265M and Adjusted EBITDA of $55-58M. Additionally, Viemed announced plans to acquire Lehan's Medical Equipment for $26M in Q3 2025, which generated $25.7M in revenue and $7.4M in Adjusted EBITDA in 2024.

Viemed Healthcare (NASDAQ: VMD) has announced a $26 million acquisition of Illinois-based Lehan's Medical Equipment, a healthcare provider specializing in home medical equipment, respiratory care, and women's health. Founded in 1946, Lehan operates three full-service locations in Northern Illinois and three sleep/CPAP setup locations in West Chicagoland and Wisconsin. The acquisition brings significant financial value, as Lehan generated $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024. The deal, expected to close in Q3 2025, includes a base purchase price of $26 million plus an estimated $2.2 million in contingent payments. Viemed will retain Lehan's 90+ employees and current owners, funding the acquisition through cash on hand and existing credit facilities.

Viemed Healthcare (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming First Quarter 2025 Earnings Conference Call. The call is scheduled for Thursday, May 8, 2025, at 11:00 a.m. EDT.

Participants can join via phone using US Toll-Free (866) 682-6100 or International +1 (862) 298-0702. A live audio webcast will be available, and a replay will be accessible in the Investor Relations section of Viemed's website after the call.